GlassScriptPhysician profile
Patricia Prince
NPI 1144259813
$265.80
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $62.65 · 2021: $43.54 · 2022: $18.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $58.64 | 2019-2021 | |
| Sanofi Pasteur INC. | $42.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.05 | 2019 | |
| Abbvie INC. | $18.45 | 2022 | |
| Boston Scientific Corporation | $17.30 | 2020 | |
| Opko Pharmaceuticals, LLC | $16.64 | 2020 | |
| Amgen INC. | $16.35 | 2019 | |
| Amarin Pharma, INC. | $16.06 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.97 | 2020 | |
| Vanda Pharmaceuticals INC. | $13.94 | 2019 | |
| Aytu Biopharma, INC. | $11.89 | 2019 | |
| Genzyme Corporation | $10.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.